DIALIZE-Outcomes — SZC null for arrhythmia-related CV events in HD; early stop (2025) — Trial Summary
DIALIZE-Outcomes — SZC null for arrhythmia-related CV events in HD; early stop (2025): Randomized, placebo-controlled trial of sodium zirconium cyclosilicate (SZC) versus placebo in adults on thrice-weekly maintenance hemodialysis with predialysis hyperkalemia (serum K ≥5.5 mmol/L). SZC started at 5
References
- Fishbane S, Dember LM, Jadoul M, et al. The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis. Kidney Int. 2025;108(4):686-694.